Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Cetuximab|DRUG: Ixabepilone
Sponsor: The Methodist Hospital Research Institute
Collaborators: Bristol-Myers Squibb